1. Lead Researcher: Jennifer Soung, M.D.

2. Study Title: An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects with Moderate to Severe Plaque Psoriasis

3. Purpose of Study: The purpose of this research study is to find out more about brodalumab in people with moderate to severe plaque psoriasis

4. Eligibility: Adults who have been diagnosed with psoriasis and who are not taking certain prohibited medications.

5. Location: Dermatology Clinical Research Center, University of California, Irvine, 1001 Hewitt Hall, Irvine CA 92697

6. Time Commitment: This study includes two different treatment groups and will last 66-67 days depending on the group. Group 1 will have a total of 16 visits and Group 2 will have a total of 11 visits, both including the screening visit. Study visits will be almost daily the first week and then every few days the following weeks. For group 1, there will be two visits that involve a 48-hour hospital stay given the administration of midazolam is sedating and requires close monitoring in a hospital setting. Otherwise, all visits will be no longer than one hour. The final portion of the study will be a follow up phone-call 2-3 weeks after the final visit.

7. Anticipated Benefits (if any): Taking part in this study may or may not make your health better. While researchers hope that brodalumab will be better than the standard (usual) treatment, there is no proof of this yet.

8. Compensation (if any): $50/visit
9. Contact Name, UCI Department, Phone Number and E-mail:
Brian Swasdibutra
UCI Department of Dermatology
949-824-7103
bswasdib@uci.edu

Signature of Lead Researcher: ____________________________ Date: ___________

IRB Approval Granted on: